News >

Published Ipilimumab/Nivolumab Data Highlight Activity in Metastatic RCC

Jason Harris
Published: Wednesday, Jul 12, 2017

Hans Hammers, MD, PhD

Hans Hammers, MD, PhD

Patients with metastatic renal cell carcinoma had an objective response rate (ORR) of 40% and a 2-year overall survival (OS) rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016 now published online in the Journal of Clinical Oncology.

Of the 12 patients in the N3I1 group who experienced at least one ipilimumab dose delay, 3 (6.4%) were due to hematologic toxicity. Fourteen (29.8%) patients in the N1I3 arm had one or more ipilimumab dose delays, 2 (4.3%) caused by hematologic toxicity.
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study [published online July 5, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.72.1985.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication